Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 9/20 | 0.57 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 2/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.43 |
| ▸ | TIPARP | Q7Z3E1 | 6/20 | 0.43 |
| ▸ | ADK | P55263 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31464932 | 1.00 | PANK3 (0.57) | PANK3CNR2RETPARP1PARP2 | |
| SCHEMBL31464986 | 1.00 | PANK3 (0.57) | PANK3CNR2RETPARP1PARP2 | |
| SCHEMBL30859837 | 1.00 | PANK3 (0.57) | PANK3CNR2RETPARP1PARP2 | |
| SCHEMBL30859867 | 0.82 | PANK3 (0.59) | PANK3CNR2PARP1PARP2TIPARP | |
| SCHEMBL31464968 | 0.82 | PANK3 (0.59) | PANK3CNR2PARP1PARP2TIPARP | |
| SCHEMBL31464996 | 0.82 | PANK3 (0.59) | PANK3CNR2PARP1PARP2TIPARP | |
| SCHEMBL30860102 | 0.82 | PANK3 (0.59) | PANK3CNR2PARP1PARP2TIPARP | |
| SCHEMBL31464955 | 0.81 | PANK3 (0.59) | PANK3CNR2RETPARP1PARP2 | |
| SCHEMBL30859861 | 0.81 | PANK3 (0.59) | PANK3CNR2RETPARP1PARP2 | |
| SCHEMBL3554489 | 0.81 | PANK3 (0.63) | PANK3CNR2RETADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109686-A1 | PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS | AZKARRA THERAPEUTICS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4594314-A1 | PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS | Azkarra Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2024073133-A1 | PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS | AZKARRA THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109686-A1 | PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS | PARP2, PARP1, PARP11 | PANK3 493/4885CNR2 120/4885RET 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.